EBV IS SOMETHING I BELIEVE WE NEED TO LOOK AT MUCH MORE CLOSELY. Epstein-Barr, or EBV, is one of the most widespread infections in the world, with around 90% of adults having been exposed. For most people it remains controlled without causing serious disease. Yet EBV is associated with several cancers and other serious conditions. So why can the same infection have such dramatically different consequences from one person to another?
A MAJOR NEW STUDY HAS GIVEN US AN IMPORTANT PIECE OF THE PUZZLE. Researchers from Baylor College of Medicine, AstraZeneca and Memorial Sloan Kettering Cancer Center analysed genetic and health information from approximately 736,000 people in the UK Biobank and All of Us programmes. Published in Nature in January 2026, the research identified 22 independent genetic loci associated with persistent EBV DNA in blood. The findings point particularly strongly towards immune-related genetic variation and antigen processing as factors influencing how effectively EBV is controlled.
YOUR GENES MAY INFLUENCE HOW WELL YOUR IMMUNE SYSTEM RESPONDS. The research identified associations involving HLA genes and other immune pathways involved in recognising and processing foreign proteins. This is fascinating to me because it provides a possible explanation for something I have often questioned: why can two people encounter the same infection yet have completely different outcomes? Our immune systems are not genetically identical, and the ability to recognise and control persistent EBV appears to vary between individuals. A separate Nature study published in February 2026, involving more than 800,000 participants, also found extensive genetic influences on persistent EBV levels and identified associations across HLA and other immune-related regions.
THIS IS WHY I THINK A POSITIVE EBV RESULT SHOULD NEVER BE VIEWED IN ISOLATION. Exposure does not mean that someone will develop cancer. What interests me is the relationship between persistent EBV activity, immune surveillance, genetics and the wider biological environment. The January Nature study found associations between persistent EBV DNA and respiratory, autoimmune, neurological and cardiovascular conditions, showing just how much broader this subject may be than cancer alone.
EBV IS ALREADY ASSOCIATED WITH SEVERAL CANCERS. These include Burkitt lymphoma, Hodgkin lymphoma, some non-Hodgkin lymphomas, nasopharyngeal carcinoma and some gastric cancers. But considering how common exposure is compared with the much smaller number of people who develop these malignancies, exposure alone clearly cannot explain the difference. Something about the host response matters.
THE IMMUNE SYSTEM MAY BE ONE OF THE CRITICAL VARIABLES. When I look at research like this, I am particularly interested in what happens when immune surveillance is less effective. If the body is unable to maintain sufficient control over persistent EBV, could prolonged activity contribute to inflammatory or disease processes in genetically susceptible individuals? The research cannot answer every part of that question, but it provides strong evidence that host genetics are involved in EBV control.
THE ASSOCIATIONS EXTEND BEYOND CANCER. The large-scale research found relationships between persistent EBV DNA and respiratory, autoimmune, neurological and cardiovascular diseases. I find this particularly important because it challenges the idea that EBV should only be considered when someone has obvious symptoms. Persistent biological activity can be a very different situation from simply knowing that someone was exposed many years ago.
WHAT INTERESTS ME MOST IS THE POSSIBILITY OF IDENTIFYING VULNERABILITY BEFORE SERIOUS DISEASE APPEARS. The genetic findings are not a crystal ball, but they provide researchers with information that could eventually help identify differences in EBV control. The Nature research itself describes this approach as a way to facilitate further investigation into EBV and other persistent infections.
I THINK THIS IS WHERE MEDICINE NEEDS TO GO. Instead of waiting until disease becomes obvious, we should investigate what is happening biologically years before diagnosis. Genetics, immune surveillance, persistent infections, inflammation and the body's ability to maintain balance may all be interconnected.
I HAVE SPENT YEARS LOOKING AT THE INTERACTION BETWEEN IMMUNITY, THE BODY'S TERRAIN AND DISEASE, AND RESEARCH LIKE THIS MAKES ME ASK MUCH BIGGER QUESTIONS. We should not simply ask whether someone has been exposed. We should be asking how their immune system is responding, whether there is evidence of persistent activity, whether genetic factors influence immune recognition and what other factors may be affecting that person's biological environment.
THIS IS ALSO WHY I BELIEVE GCMAF IS CERTAINLY WORTH EXPLORING IF YOU HAVE EBV. From my own years of studying GcMAF and immune function, I am particularly interested in its proposed relationship with macrophage activation and immune surveillance. Macrophages are important immune cells, and the immune response to persistent EBV involves multiple cell types and pathways. Many people who have used GcMAF in relation to EBV report no further outbreaks, with people who have remained free of outbreaks for as long as a decade. These are experiences I find particularly interesting because they raise questions about whether supporting immune function helps people maintain better long-term control. I believe GcMAF is therefore certainly worth exploring as an area of research for people dealing with persistent or recurrent EBV. If you are interested in exploring GcMAF further, you may also wish to the website GcMaf.com or join the Facebook group, GcMAF Research, where you will find shared research and information relating to GcMAF and immune function. GcMAF Research Facebook group https://www.facebook.com/share/g/19PoQ2ogZn/
WE DO NOT YET HAVE ALL THE ANSWERS. But finding 22 independent genetic loci associated with persistent EBV DNA in a study involving hundreds of thousands of people is an important step towards understanding why one extremely common infection can have such different consequences between individuals.
AND THAT LEAVES ME WITH A QUESTION: if our genetic makeup can influence how effectively our bodies control an infection carried by the majority of the population, how many other persistent infections might also interact with individual genetics and immune function in ways we have not yet recognised?
That is a question I will be watching very closely.
Please share this information to help increase awareness.
Copyright Maryjayne Aria, author of Immune Health, Terrain and GcMAF.
